Volume 3, Issue 1

Original research papers

Radiation Protection


Ferdinand Sudbrock, Klaus Schomäcker, Thomas Fischer, Alexander Drzezga

Pages: 23-26

DOI: 10.21175/RadJ.2018.01.005

Received: 10 FEB 2017, Received revised: 17 APR 2017, Accepted: 22 MAY 2017, Published online: 2 APR 2018

Therapeutic treatment with radionuclides leads to radiation exposure. Exposure in the vicinity of patients undergoing radionuclide therapy for thyroid carcinoma needs to be discussed due to the high amount of radioactivity administered to the patient. This study presents the estimations of annual effective doses received by members of the public not directly involved in treatment procedures after patient discharge from our Department of Nuclear Medicine. After a few days of in-patient stay, the exposure is in general very low and a dedicated supervision of the patient after discharge is dispensable.
  1. J. C. Harbert and N. Wells, “Radiation exposure to the family of radioactive patient,” J. Nucl. Med., vol. 15, no. 10, pp. 887 – 888, Oct. 1974.
    PMid: 4418007
  2. C. M. Culver and H. J. Dworkin, “Radiation safety considerations for post-Iodine-131 hyperthyroid therapy,” J. Nucl. Med., vol 32, no. 1, pp. 169 – 173, Jan. 1991.
    PMid: 1988627
  3. M. Salvatori and G. Lucignani, “Radiation exposure, protection and risk from nuclear medicine procedures,” Eur. J. Nucl. Med., vol 37, no. 6, pp 1225 – 1231, Jun. 2010.
    DOI: 10.1007/s00259-010-1474-5
    PMid: 20411257
  4. M. Pacilio, L. Bianciardia, V. Panichelli, G. Argiro, and C. Cipriani, “Management of 131I therapy for thyroid cancer: cumulative dose from in-patients, discharge planning and personnel requirements,” Nuc. Med. Commun., vol. 26, no. 7, pp 623 – 631, Jul. 2005.
    DOI: 10.1097/01.mnm.0000167909.69095.c9
    PMid: 15942483
  5. S. F. Barrington, A. G. Kettle, M. J. O’Doherty, C. P. Wells, A. J. R. Somer, and A. J. Coakley, “Radiation does rates from patients receiving iodine-131 therapy for carcinoma of the thyroid,” Eur. J. Nucl. Med., vol. 23, no. 2, pp. 123 – 130, Feb. 1996.
    DOI: 10.1007/BF01731834
    PMid: 8925845
  6. S. F. Barrington et al., “Radiation exposure of the families of outpatients treated with radioiodine (iodine-131) for hyperthyroidism,” Eur. J. Nucl. Med., vol. 26, no. 7, pp. 686 – 692, Jun. 1999.
    DOI: 10.1007/s002590050438
    PMid: 10398815
  7. P. W. Grigsby, B. A. Siegel, S. Baker, J. O. Eichling, “Radiation exposure from outpatient radioactive iodine (131I) therapy for thyroid carcinoma,” J. Am. Med. Assoc., vol. 283, no. 17, pp. 2272 – 2274, May 2000.
    DOI: 10.1001/jama.283.17.2272
    PMid: 10807387
  8. D. D`Alessio, C. Giliberti, M. Benassi, L. Strigari, “Potential third-party radiation exposure from patients undergoing therapy with 131I for thyroid cancer or metastases,” Health Phys., vol. 108, no. 3, pp. 319 – 325, Mar. 2015.
    DOI: 10.1097/HP.0000000000000210
    PMid: 25627943
  9. F. Sudbrock, F. Boldt, C. Kobe, J. Hammes, W. Eschner, H. Schicha, “Die Strahlenexposition in der Umgebung von Patienten nach Applikation verschiedener Radiopharmaka. Teil 2 Nuklearmedizinische Therapien,” Nuklearmedizin, vol. 48, pp. 17 – 25, 2009. (F. Sudbrock, F. Boldt, C. Kobe, J. Hammes, W. Eschner, H. Schicha, “Radiation exposure in the environment of patients after application of radiopharmaceuticals,” Nucl. med., vol. 48, pp. 17 – 25, 2009.).
  10. K. Uhrhan, A. Drzezga, and F. Sudbrock, “The patient as a radioactive source: an intercomparison of survey meters for measurements in nuclear medicine,” Radiat. Prot. Dosimetry, vol. 162, no. 1-2, pp. 101 – 104, Jul. 2014.
    DOI: 10.1093/rpd/ncu238
    PMid: 25071244
  11. J. Willegaignon de Amorim de Carvalho et al., “Could the treatment of differentiated thyroid carcinoma with 3.7 and 5.5 GBq of (131I) NaI, on an outpatient basis, be safe?” Nucl. Med. Commun., vol. 30, no. 7, pp. 533 – 541, Jul. 2009.
    DOI: 10.1097/MNM.0b013e32832b79bc
    PMid: 19436231
  12. C. E. Williams and A. F. Woodward, “Management of the helpless patient after radioiodine ablation therapy - are we being too strict?” Nucl. Med. Comm. vol. 26, no. 10, pp. 925 – 928, Oct. 2005.
    DOI: 10.1097/00006231-200510000-00012
    PMid: 16160653
  13. C. J. Marriott, C. E. Webber, and K. Y. Gulenchyn, “Radiation exposure for ‘caregivers’ during high-dose outpatient radioiodine therapy,” Rad. Prot. Dosimetry, vol 123, no. 1, pp. 62 – 67, Jan. 2007.
    DOI: 10.1093/rpd/ncl084
    PMid: 16825250
  14. K. H. Jeong et al., “Estimation of external radiation dose to caregivers of patients treated with radioiodine after thyroidectomy,” Health Phys., vol. 106, no. 4, pp. 466 – 474, Apr. 2014.
    DOI: 10.1097/HP.0b013e3182a415eb
    PMid: 24562067
  15. K. Schomäcker et al., “Exhalation of 131I after radioiodine therapy: measurements in exhaled air and dosimetric considerations,” Eur. J. Nucl. Med. Mol. Im., vol. 38, no. 12, pp. 2165 – 2172, Dec. 2011.
    DOI: 10.1007/s00259-011-1888-8
    PMid: 21847636